Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Accounts Payables (2020 - 2026)

Immuneering's Accounts Payables history spans 7 years, with the latest figure at $1.5 million for Q1 2026.

  • On a quarterly basis, Accounts Payables rose 10.88% to $1.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.5 million, a 10.88% increase, with the full-year FY2025 number at $1.5 million, down 21.23% from a year prior.
  • Accounts Payables came in at $1.5 million for Q1 2026, down from $1.5 million in the prior quarter.
  • The five-year high for Accounts Payables was $3.2 million in Q4 2022, with the low at $1.2 million in Q2 2022.
  • Historically, Accounts Payables has averaged $2.1 million across 5 years, with a median of $2.0 million in 2024.
  • Biggest five-year swings in Accounts Payables: surged 126.24% in 2022 and later crashed 42.29% in 2025.
  • Year by year, Accounts Payables stood at $3.2 million in 2022, then crashed by 33.06% to $2.1 million in 2023, then dropped by 7.25% to $2.0 million in 2024, then decreased by 21.23% to $1.5 million in 2025, then fell by 5.81% to $1.5 million in 2026.
  • Business Quant data shows Accounts Payables for IMRX at $1.5 million in Q1 2026, $1.5 million in Q4 2025, and $1.6 million in Q3 2025.